Unichem Laboratories Receives Appellate Order on Tax Dispute, Penalty Amounting to ₹87 Crore
Unichem Laboratories received an appellate order on a tax dispute. The order disallowed a penalty of ₹87.07 crore and interest of ₹6.59 crore. The company believes there will be no material financial impact and plans to appeal the order.
The announcement involves a substantial penalty and interest amount, which could have a significant financial impact if the appeal is unsuccessful. However, the company's statement that there will be no material impact and their intention to appeal mitigates the immediate impact.
The company has received an order from the Commissioner (Appeals) regarding a tax dispute. While a significant penalty and interest were disallowed, the company's plan to appeal and the assertion of no material impact suggest a neutral stance.
Unichem Laboratories Limited has received an Order-In-Appeal from the Commissioner (Appeals), Thane, concerning a tax dispute related to the cross-charge of common services. The order disallowed a penalty of ₹87,07,09,556 under Section 74(1) and Section 122(2)(b) of the CGST Act, 2017, along with an interest liability of ₹6,58,76,590.
The company was informed of the order on 18th September 2026, after 2:00 p.m. The alleged violations include delayed payment of tax liability for supplies, contravening Section 13 of the CGST Act, 2017, and Rule 47 of the CGST Rules, 2017, leading to the non-payment of interest. A penalty of ₹87,07,09,556 under the CGST Act and the corresponding section of the Maharashtra SGST Act was also levied.
Unichem Laboratories stated that there will be no material impact on the financial, operational, or other activities of the company. Based on legal advice, the company plans to take appropriate remedial steps, including filing an appeal against the said order within the prescribed timelines.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.